Investigational drug · Phase 3
JSKN003
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
11
Any phase or sponsor naming "JSKN003"
First trial start
2023
Mar 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JSKN003", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Colorectal Cancer
- Advanced Solid Tumor
- HER2-positive Gastric Cancer
- Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancers
- Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
- HER2-positive Recurrent or Metastatic Breast Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Colorectal cancer · Ovarian cancer · Stomach and esophageal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JSKN003" as an intervention, largest first.
- Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsActive, not recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT05744427 · 725 participants (planned) · Start Mar 15, 2023 · Primary completion Jul 30, 2026
Drug: JSKN003 · For: Advanced Solid Tumor
Sites: Beijing, China; Changsha, China; Fuzhou, China · 34 sites in all
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerPivotal-lookingNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06751485 · 430 participants (planned) · Start Jan 15, 2025 · Primary completion Dec 30, 2026
Drug: JSKN003; Doxorubicin and 2 more · For: Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsPivotal-lookingRecruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06079983 · 400 participants (planned) · Start Dec 1, 2023 · Primary completion Apr 1, 2026
Drug: JSKN003; Capecitabine tablets and 5 more · For: Breast Cancer
Sites: Guangzhou, China; Shanghai, China; Anyang, China · 87 sites in all
- JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerPivotal-lookingRecruiting
Shanghai JMT-Bio Inc.Industry
NCT06846437 · 228 participants (planned) · Start Feb 18, 2025 · Primary completion Oct 13, 2026
Drug: JSKN003; Trastuzumab emtansine (T-DM1) · For: Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Sites: Shanghai, China
- A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07283198 · 160 participants (planned) · Start Dec 10, 2025 · Primary completion Aug 30, 2027
Drug: JSKN033 Injection · For: Non Small Cell Lung Cancer (NSCLC)
- JSKN003 Combined Treatment of HER2-positive Gastric CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06998771 · 153 participants (planned) · Start Jun 15, 2025 · Primary completion Jun 30, 2028
Drug: JSKN003; KN026 and 5 more · For: HER2-positive Gastric Cancer
- JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and IrinotecanPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07384377 · 123 participants (planned) · Start Feb 6, 2026 · Primary completion Nov 30, 2027
Drug: JSKN003; Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. · For: HER2-positive Colorectal Cancer
Alphamab (Australia) Co Pty Ltd.Industry
NCT05494918 · 62 participants · Start Sep 2, 2022 · Primary completion Apr 15, 2025
Drug: JSKN003 · For: Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Perth, Australia
- A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07545044 · 60 participants (planned) · Start May 30, 2026 · Primary completion May 29, 2027
Drug: JSKN003; Trastuzumab and 2 more · For: HER2-positive Recurrent or Metastatic Breast Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.
Ji X, Yang Y, Ma C, et al. · Cancer Chemother Pharmacol 2026
- Adverse events induced by the subcutaneous HER2-targeted antibody-drug conjugate JSKN033 in a male patient with breast cancer: A case report.
Yang R, Zhang J, Wang Y · Oncol Lett 2026
- A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy.
Xue Q, Peng J, Dai W, et al. · RSC Chem Biol 2025
- Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.
Yang Q, Liu Y · RSC Med Chem 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.